Joseph J. Ferra Jr. - 15 May 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
15 May 2025
Net transactions value
-$690
Form type
4
Filing time
19 May 2025, 16:10:05 UTC
Previous filing
18 Mar 2025
Next filing
18 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ferra Joseph J Jr CHIEF EXECUTIVE OFFICER, Director C/O ELEVATION ONCOLOGY, INC., 101 FEDERAL STREET, SUITE 1900, BOSTON /s/ Robert Yang, Attorney-in-Fact 19 May 2025 0001733790

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +6,250 +4.7% 139,455 15 May 2025 Direct F1
transaction ELEV Common Stock Tax liability $690 -2,303 -1.7% $0.2998 137,152 15 May 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -6,250 -8.3% $0.000000 68,750 15 May 2025 Common Stock 6,250 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.